TickerFacts.

Evommune, Inc. (EVMN): Shareholders' Equity

Annual figures by period end, from SEC filings.

$205.57M
As of 2025-12-31
$277.59M
As of 2026-06-30
2024-12-31: -$144.24M2025-12-31: $205.57M$205.57M
2024-12-31 Shareholders' Equity (USD) 2025-12-31
Period endedShareholders' EquityChange YoYSource filing
2025-12-31$205.57Mn/m2026-03-05, Balance as of period end
2024-12-31-$144.24Mn/a2026-03-05, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
Evommune, Inc. (EVMN)2025-12-31$205.57Mn/m
Tonix Pharmaceuticals Holding Corp. (TNXP)2025-12-31$245.15M+75.7%
Emmaus Life Sciences, Inc. (EMMA)2025-12-31-$63.61Mn/m
CV Sciences, Inc. (CVSI)2025-12-31$1.47M-18.2%
Pyxis Oncology, Inc. (PYXS)2025-12-31$53.41M-55.8%
Prelude Therapeutics Inc (PRLD)2025-12-31$68.64M-47.8%
Arbutus Biopharma Corp (ABUS)2025-12-31$76.58M-21.4%
Opus Genetics, Inc. (IRD)2025-12-31$15.35M+128.3%
Jaguar Health, Inc. (JAGX)2025-12-31-$18.69Mn/m

Compare EVMN, TNXP, EMMA, CVSI side by side · Screen every company in Pharmaceutical Preparations ↗